Published in Biotech Business Week, January 8th, 2007
These studies were presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando.
"It is becoming ever clearer that multiple epigenetic pathways typically operate in parallel to silence tumor suppressor genes in cancer cells," said Dr. Andrew Allen, Pharmion's chief medical officer. "By combining epigenetic therapies, such as DNA demethylating agents and HDAC...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.